JPMorgan and Credit Suisse downgraded Clovis Oncology Inc. (Nasdaq: CLVS) after a Food and Drug Administration advisory committee recommended against approval of the non-small cell lung cancer treatment rociletinib. Shares of the biopharmaceutical tumbled $1.26 to $12.98.
Clovis Oncology downgraded
April 13, 2016 at 12:28 PM EDT
